HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

microsomal triglyceride transfer protein

Subscribe to New Research on microsomal triglyceride transfer protein

consists of 97-kDa catalytic subunit associated with protein-disulfide isomerase; transfers triglycerides between lipid membranes; amino acid sequence in first source; do not confuse with MTP protein, lipid transfer protein, or LTP-I protein

Also Known As:

MTP triglyceride carrier; MTTP protein, human; Mttp protein, mouse; Mttp protein, rat; microsomal TG transfer protein; microsomal triglyceride transfer protein, human; microsomal triglyceride transfer protein, mouse; microsomal triglyceride transfer protein, rat

Networked: 93 relevant articles (2 outcomes, 3 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 60567
  - Carrier Proteins: 7962
    - microsomal triglyceride transfer protein: 93

Experts

1.	Rader, Daniel J: 3 articles (08/2010 - 01/2007)
2.	Mirandola, Silvia: 3 articles (01/2010 - 05/2006)
3.	Alberti, Alfredo: 3 articles (01/2010 - 05/2006)
4.	Iqbal, Jahangir: 3 articles (06/2008 - 05/2006)
5.	Hussain, M Mahmood: 3 articles (06/2008 - 05/2006)
6.	Kang, Sohye: 3 articles (11/2006 - 05/2002)
7.	Davis, Roger A: 3 articles (11/2006 - 05/2002)
8.	Berriot-Varoqueaux, N: 3 articles (11/2001 - 01/2000)
9.	Aggerbeck, L P: 3 articles (11/2001 - 01/2000)
10.	Dougan, Stephanie K: 2 articles (08/2010 - 06/2008)

Related Diseases

1.	Fibrosis (Cirrhosis) 09/01/2009 - "RESULTS: Long-term combination therapy with EZ and AC significantly reduced steatosis, inflammation and fibrosis in the liver, compared with long-term monotherapy with either drug, in an HFD-induced NAFLD mouse model; the combination therapy also significantly increased the expression of microsomal triglyceride transfer protein (MTP) and peroxisome proliferators-activated receptor-alpha1 (PPAR-alpha1) in the liver, compared with either monotherapy, which may have led to the improvement in lipid metabolic disorder seen in this model. " 04/01/2008 - "Although no genetic associations with advanced NAFLD have been replicated in large studies, preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, tumor necrosis factor-alpha, transforming growth factor-beta, and angiotensinogen may be associated with steatohepatitis and/or fibrosis. " 02/01/2007 - "Preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, tumor necrosis factor alpha, transforming growth factor beta, and angiotensinogen may be associated with steatohepatitis or hepatic fibrosis or both." 11/01/2006 - "Preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, TNF-alpha, transforming growth factor-beta, and angiotensinogen may be associated with steatohepatitis and/or fibrosis." Order ALL the reference details at left...
2.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/11/2007 - "Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia." 01/11/2007 - "METHODS: We conducted a dose-escalation study to examine the safety, tolerability, and effects on lipid levels of BMS-201038, an inhibitor of the microsomal triglyceride transfer protein, in six patients with homozygous familial hypercholesterolemia. " 07/01/2000 - "A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP -493G/T) influences lipoprotein phenotype in familial hypercholesterolemia." 11/09/2001 - "To examine whether a microsomal triglyceride transfer protein (MTP)-inhibitor is effective in patients with homozygous familial hypercholesterolemia, we administered (2S)-2-cyclopentyl-2-[4-[(2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1S)-2-hydroxy-1-phenylethyl]ethanamide (Implitapide), a new MTP inhibitor, to low-density lipoprotein (LDL)-receptor-deficient Watanabe heritable hyperlipidemic (WHHL) rabbits at doses of 3, 6, and 12 mg/kg for 4 weeks. " 01/11/2007 - "CONCLUSIONS: Inhibition of the microsomal triglyceride transfer protein by BMS-201038 resulted in the reduction of LDL cholesterol levels in patients with homozygous familial hypercholesterolemia, owing to reduced production of apolipoprotein B. " Order ALL the reference details at left...
3.	Inflammation 09/01/2009 - "RESULTS: Long-term combination therapy with EZ and AC significantly reduced steatosis, inflammation and fibrosis in the liver, compared with long-term monotherapy with either drug, in an HFD-induced NAFLD mouse model; the combination therapy also significantly increased the expression of microsomal triglyceride transfer protein (MTP) and peroxisome proliferators-activated receptor-alpha1 (PPAR-alpha1) in the liver, compared with either monotherapy, which may have led to the improvement in lipid metabolic disorder seen in this model. " 06/01/2008 - "SUMMARY: Microsomal triglyceride transfer protein is a target to lower plasma lipids and to reduce inflammation in certain immune disorders. " 12/01/2008 - "PURPOSE OF REVIEW: Microsomal triglyceride transfer protein (MTP), a chaperone for the biosynthesis of apolipoprotein B lipoproteins and CD1d, is a therapeutic candidate to decrease plasma lipids and to diminish inflammation. " Order ALL the reference details at left...
4.	Fatty Liver 06/01/2010 - "Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model." 06/01/2006 - "Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients." 02/01/2002 - "Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats." 10/01/2000 - "Etiology of fatty liver in dairy cattle: effects of nutritional and hormonal status on hepatic microsomal triglyceride transfer protein." 08/01/2000 - "Microsomal triglyceride transfer protein (MTP) is necessary for the assembly and secretion of VLDL and when the protein is not functional, such as in abetalipoproteinaemia, a steatohepatitis occurs. " Order ALL the reference details at left...
5.	Hepatocellular Carcinoma (Hepatoma) 06/01/1997 - "Studies carried out in a variety of heterologous expression systems, as well as the use of microsomal triglyceride transfer protein inhibitors in hepatoma cell lines, have been critical to this progress. " 08/15/2003 - "ARP-1/COUP-TF II determines hepatoma phenotype by acting as both a transcriptional repressor of microsomal triglyceride transfer protein and an inducer of CYP7A1." 04/15/2002 - "Distribution of microsomal triglyceride transfer protein within sub-endoplasmic reticulum regions in human hepatoma cells." 08/06/2002 - "The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein b100." 07/01/2001 - "We used the HepG2 hepatoma cell line to: (1) determine the time required until levels of secreted apo B-100 and TG declined significantly, (2) examine the relation to the mass of cellular cholesteryl ester (CE) and (3) test microsomal triglyceride transfer protein (MTP) activity which leads to decreased apo B-100 production. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Lipoproteins (Lipoprotein)
2.	LDL Receptors (LDL Receptor)
3.	implitapide
4.	Peroxisome Proliferators
5.	Transforming Growth Factor beta (TGF-beta)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Angiotensinogen
8.	superoxide dismutase 2
9.	endotoxin receptor
10.	BMS201038

blog comments powered by Disqus

TREATMENT OPTIONS
for Fibrosis,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1570 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>